Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia ; volume:99 ; number:6 ; day:15 ; month:4 ; year:2020 ; pages:1415-1417 ; date:6.2020
Annals of hematology ; 99, Heft 6 (15.4.2020), 1415-1417, 6.2020
- Urheber
-
Gupta, Charu
Kaulfuss, Stefan
Görlich, Kerstin
Othman, Basem
Chaturvedi, Anuhar
Heuser, Michael
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-020-04001-w
- URN
-
urn:nbn:de:101:1-2020072319195724396602
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gupta, Charu
- Kaulfuss, Stefan
- Görlich, Kerstin
- Othman, Basem
- Chaturvedi, Anuhar
- Heuser, Michael
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mechanistic and therapeutic insights into IDH1 mutant acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia
Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
Mechanistic and therapeutic insights into IDH1 mutant acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia
Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
Mechanistic and therapeutic insights into IDH1 mutant acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia
Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia